Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Abstract Text:

Michael T Heneka,Gary E Landreth,Michael ,

The finding that activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component. The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma. Several lines of evidence from experiments using AD-related transgenic cellular and animal models have supported this hypothesis. The capacity of PPARgamma agonists to elicit anti-inflammatory, anti-amyloidogenic and insulin-sensitizing effects might account for their observed protective effects. Several clinical trials employing PPARgamma agonists have yielded promising results, and further trials are in preparation. Positive outcomes following PPARgamma administration have been obtained in animal models of other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis, both of which are associated with a considerable degree of neuroinflammation. Finally, activation of PPARgamma has been found to be protective in several models of multiple sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in patients with multiple sclerosis.

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Publishing Authors By Initials

MT Heneka,GE Landreth,M ,

For similar pharmaceutical preparations research abstracts see: pharmaceutical preparations research

PUBMED ID PMID:

MEDLINE DATE:

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Journal Published:

PUBLICATION TYPE: Review

Journal: Nature clinical practice. Neurology

VOLUME: 3

Page Numbers: 496-504

Journal Abbreviation:

ISSN: 1745-8358

DAY: 3

MONTH: Sep

YEAR: 2007

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101261799

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Keywords Mesh Terms:

KEYWORDS: Pharmaceutical Preparations

MESH TERMS: metabolism

Chemical & Substance for Abstract: Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Information

Substance Name: Pharmaceutical Preparations

Registry Number: 0

Grant and Affiliation Information for Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.

AFFILIATION: Department of Neurology, University of Münster, Germany. heneka@uni-muenster.de

Country: England

AGENCY: United States NIA

GRANT: AG16740

ACRONYM: AG

MEDLINETA: Nat Clin Pract Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders Related Publications

• A pilot group therapy for functional memory disorder.
• Combined semantic dementia and apraxia in a patient with frontotemporal lobar degeneration.
• Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.